The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review

Nutrition and Cancer

Volumn 68, Issue 6, 2016, Pages 892-917

  Razavi Azarkhiavi, Kamal ^a   Iranshahy, Milad ^a   Sahebkar, Amirhossein ^a   Shirani, Kobra ^a   Karimi, Gholamreza ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

(6) GINGEROL; 7 MONOHYDROXYETHYLRUTOSIDE; BAICALEIN; CAFFEIC ACID PHENETHYL ESTER; CATECHIN; CHRYSIN; CHRYSOERIOL; CURCUMIN; DOXORUBICIN; EUGENOL; FLAVAGLINE DERIVATIVE; FLAVONOLIGNAN; HESPERIDIN; HYDROXYTYROSOL; ISORHAMNETIN; KAEMPFEROL; LUTEOLIN; NARINGENIN; OLEUROPEIN; OLIVE OIL; PHENOL DERIVATIVE; PHENYLPROPANOID DERIVATIVE; PLANTAINOSIDE D; QUERCETIN; RESVERATROL; RUTOSIDE; SALIDROSIDE; SESAMOL; TETRAHYDROXYSTILBENE GLUCOSIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; ANTIOXIDANT; CARDIOTONIC AGENT; FLAVONOID;

CARDIOTOXICITY; DRACOCEPHALUM TANGUTICUM; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; REVIEW; TRADITIONAL MEDICINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; DIETARY SUPPLEMENT; METABOLISM;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIOXIDANTS; CARDIOTONIC AGENTS; CARDIOTOXICITY; DIETARY SUPPLEMENTS; DOXORUBICIN; FLAVONOIDS; HUMANS; MODELS, CARDIOVASCULAR; PHENOLS;

EID: 84978790767     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2016.1187280     Document Type: Review

References (179)

1. G.Bonadonna, S.Monfardini, M.De Lena, F.Fossati-Bellani, and G.Beretta: Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 30(10), 2572–2582, 1970.
2. F.S.Carvalho, A.Burgeiro, R.Garcia, A.J.Moreno, R.A.Carvalho, et al.: Doxorubicin‐induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34(1), 106–135, 2014.
3. F.Villani, G.Beretta, and A.Guindani: Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals. Cancer Chemoth Pharm 3(4), 249–251, 1979.
4. M.Bristow, M.Billingham, J.Mason, and J.Daniels: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62(6), 873–879, 1978.
5. G.C.Pereira, A.M.Silva, C.V.Diogo, F.S.Carvalho, P.Monteiro, et al.: Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr Pharm Des 17(20), 2113–2129, 2011.
6. J.Alexander, N.Dainiak, H.J.Berger, L.Goldman, D.Johnstone, et al.: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300(6), 278–283, 1979.
7. K.Chatterjee, J.Zhang, N.Honbo, and J.S.Karliner: Doxorubicin cardiomyopathy. Cardiology 115(2), 155–162, 2009.
8. K.B.Wallace: Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93(3), 105–115, 2003.
9. E.T.Yeh, A.T.Tong, D.J.Lenihan, S.W.Yusuf, J.Swafford, et al.: Cardiovascular complications of cancer therapy diagnosis, pathogenesis, and management. Circulation 109(25), 3122–3131, 2004.
10. A.C.Childs, S.L.Phaneuf, A.J.Dirks, T.Phillips, and C.Leeuwenburgh: Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res 62(16), 4592–4598, 2002.
11. A.V.Pointon, T.M.Walker, K.M.Phillips, J.Luo, J.Riley, et al.: Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One 5(9), 12733, 2010.
12. S.Zhang, X.Liu, T.Bawa-Khalfe, L.-S.Lu, Y.L.Lyu, et al.: Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Med 18(11), 1639–1642, 2012.
13. P.Menna, S.Recalcati, G.Cairo, and G.Minotti: An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7(2), 80–85, 2007.
14. E.Raschi, V.Vasina, M.G.Ursino, G.Boriani, A.Martoni, et al.: Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 125(2), 196–218, 2010.
15. D.Lebrecht and U.A.Walker: Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 7(2), 108–113, 2007.
16. D.Iarussi, P.Indolfi, F.Casale, P.Coppolino, M.Tedesco, et al.: Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem 8(13), 1649–1660, 2001.
17. G.Takemura and H.Fujiwara: Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49(5), 330–352, 2007.
18. J.Xiao, G.B.Sun, B.Sun, Y.Wu, L.He, et al.: Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. Toxicology 292(1), 53–62, 2012.
19. L.Bravo: Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 56(11), 317–333, 1998.
20. M.A.Soobrattee, V.S.Neergheen, A.Luximon-Ramma, O.I.Aruoma, and T.Bahorun: Phenolics as potential antioxidant therapeutic agents: mechanism and actions. Mutat Res Fund Mol Mech Mut 579(1), 200–213, 2005.
21. R.J.Williams, J.P.Spencer, and C.Rice-Evans: Flavonoids: antioxidants or signalling molecules? Free Rad Biol Med 36(7), 838–849, 2004.
22. J.Dai and R.J.Mumper: Plant phenolics: extraction, analysis and their antioxidant and anticancer properties. Molecules 15(10), 7313–7352, 2010.
23. S.H.Thilakarathna and H.Rupasinghe: Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients 5(9), 3367–3387, 2013.
24. C.F.Lourenco, B.Gago, R.M.Barbosa, V.de Freitas, and J.Laranjinha: LDL isolated from plasma-loaded red wine procyanidins resist lipid oxidation and tocopherol depletion. J Agric Food Chem 56(10), 3798–3804, 2008.
25. S.H.Thilakarathna, Y.Wang, H.Rupasinghe, and K.Ghanam: Apple peel flavonoid-and triterpene-enriched extracts differentially affect cholesterol homeostasis in hamsters. J Funct Foods 4(4), 963–971, 2012.
26. C.Noll, J.Hamelet, E.Matulewicz, J.-L.Paul, J.-M.Delabar, et al.: Effects of red wine polyphenolic compounds on paraoxonase-1 and lectin-like oxidized low-density lipoprotein receptor-1 in hyperhomocysteinemic mice. J Nutr Biochem 20(8), 586–596, 2009.
27. J.J.Peterson, J.T.Dwyer, P.F.Jacques, and M.L.McCullough: Associations between flavonoids and cardiovascular disease incidence or mortality in European and US populations. Nutr Rev 70(9), 491–508, 2012.
28. P.Lapchak, P.Maher, D.Schubert, and J.Zivin: Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 150(3), 585–591, 2007.
29. H.-M.Chen, J.-H.Hsu, S.-F.Liou, T.-J.Chen, L.-Y.Chen, et al.: Baicalein, an active component of Scutellaria baicalensis Georgi, prevents lysophosphatidylcholine-induced cardiac injury by reducing reactive oxygen species production, calcium overload and apoptosis via MAPK pathways. BMC Complement Altern Med 14(1), 233, 2014.
30. W.T.Chang, J.Li, H.H.Haung, H.Liu, M.Han, et al.: Baicalein protects against doxorubicin-induced cardiotoxicity by attenuation of mitochondrial oxidant injury and JNK activation. J Cell Biochem 112(10), 2873–2881, 2011.
31. S.Aroui, D.Mili, S.Brahim, M.D.Waard, and A.Kenani: Doxorubicin coupled to penetratin promotes apoptosis in CHO cells by a mechanism involving c-Jun NH2-terminal kinase. Biochem Biophys Res Commun 396(4), 908–914, 2010.
32. Y.Yamamoto, Y.Hoshino, T.Ito, T.Nariai, T.Mohri, et al.: Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res 79(1), 89–96, 2008.
33. S.Kalender, Y.Kalender, A.Ates, M.Yel, E.Olcay, et al.: Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats. Braz J Med Biol Res 35(11), 1379–1387, 2002.
34. O.Kozluca, E.Olcay, S.SSürücü, Z.Güran, T.Kulaksiz, et al.: Prevention of doxorubicin induced cardiotoxicity by catechin. Cancer Lett 99(1), 1–6, 1996.
35. Y.Du and H.Lou: Catechin and proanthocyanidin B4 from grape seeds prevent doxorubicin-induced toxicity in cardiomyocytes. Eur J Pharm 591(1), 96–101, 2008.
36. X.Li, Q.Huang, C.-N.Ong, X.-F.Yang, and H.-M.Shen: Chrysin sensitizes tumor necrosis factor-α-induced apoptosis in human tumor cells via suppression of nuclear factor-kappaB. Cancer Lett 293(1), 109–116, 2010.
37. B.Y.Khoo, S.L.Chua, and P.Balaram: Apoptotic effects of chrysin in human cancer cell lines. Int J Mol Sci 11(5), 2188–2199, 2010.
38. H.Cho, C.-W.Yun, W.-K.Park, J.-Y.Kong, K.S.Kim, et al.: Modulation of the activity of pro-inflammatory enzymes, COX-2 and iNOS, by chrysin derivatives. Pharmacol Res 49(1), 37–43, 2004.
39. G.Pushpavalli, P.Kalaiarasi, C.Veeramani, and K.V.Pugalendi: Effect of chrysin on hepatoprotective and antioxidant status in D-galactosamine-induced hepatitis in rats. Eur J Pharmacol 631(1), 36–41, 2010.
40. E.M.Mantawy, W.M.El-Bakly, A.Esmat, A.M.Badr, and E.El-Demerdash: Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Eur J Pharmacol 728, 107–118, 2014.
41. Y.Yang, X.Zhou, M.Xiao, Z.Hong, Q.Gong, et al.: Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro. J Huazhong Univ Sci Technol Med Sci 30, 734–740, 2010.
42. Z.Liu, X.-D.Song, Y.Xin, X.-J.Wang, H.Yu, et al.: Protective effect of chrysoeriol against doxorubicin-induced cardiotoxicity in vitro. Chin Med J (Engl) 122(21), 2652–2656, 2009.
43. S.B.Etcheverry, E.G.Ferrer, L.Naso, J.Rivadeneira, V.Salinas, et al.: Antioxidant effects of the VO (IV) hesperidin complex and its role in cancer chemoprevention. JBIC J Biol Inorg Chem 13(3), 435–447, 2008.
44. K.Kalpana, M.Srinivasan, and V.P.Menon: Evaluation of antioxidant activity of hesperidin and its protective effect on H2O2 induced oxidative damage on pBR322 DNA and RBC cellular membrane. Mol Cell Biochem 323(1–2), 21–29, 2009.
45. I.T.Abdel-Raheem and A.A.Abdel-Ghany: Hesperidin alleviates doxorubicin-induced cardiotoxicity in rats. J Egypt Natl Canc Inst 21(2), 175–184, 2009.
46. W.G.Hozayen and H.S.A.Seif: Protective effects of rutin and hesperidin against doxorubicin-induced lipodystrophy and cardiotoxicity in albino rats. J Am Sci 7(12), 765–775, 2011.
47. B.Ameer, R.A.Weintraub, J.V.Johnson, R.A.Yost, and R.L.Rouseff: Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharm Ther 60(1), 34–40, 1996.
48. N.-K.Lee, S.-H.Choi, S.-H.Park, E.-K.Park, and D.-H.Kim: Antiallergic activity of hesperidin is activated by intestinal microflora. Pharmacology 71(4), 174–180, 2004.
49. P.Trivedi, S.Kushwaha, D.Tripathi, and G.Jena: Cardioprotective effects of hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat. Cardiovasc Toxicol 11(3), 215–225, 2011.
50. G.Zhao, J.Duan, Y.Xie, G.Lin, H.Luo, et al.: Effects of solid dispersion and self-emulsifying formulations on the solubility, dissolution, permeability and pharmacokinetics of isorhamnetin, quercetin and kaempferol in total flavones of Hippophae rhamnoides L. Drug Dev Ind Pharm 39(7), 1037–1045, 2013.
51. V.S.Panda and S.R.Naik: Evaluation of cardioprotective activity of Ginkgo biloba and Ocimum sanctum in rodents. Altern Med Rev 14(2), 161, 2009.
52. X.Han, S.Gao, Y.Cheng, Y.Sun, W.Liu, et al.: Protective effect of naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyocytes. Biosci Trends 6(1), 19–25, 2012.
53. J.Sun, G.Sun, X.Meng, H.Wang, Y.Luo, et al.: Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. PLoS One 8(5), e64526, 2013.
54. D.K.Morrison: MAP kinase pathways. Cold Spring Harb Perspect Biol 4(11), e11254, 2012.
55. M.Olszewska: Separation of quercetin, sexangularetin, kaempferol and isorhamnetin for simultaneous HPLC determination of flavonoid aglycones in inflorescences, leaves and fruits of three< i>Sorbusspecies. J Pharm Biomed Anal 48(3), 629–635, 2008.
56. S.Keyhanian and E.Stahl-Biskup: Phenolic constituents in dried flowers of aloe vera (Aloe barbadensis) and their in vitro antioxidative capacity. Planta Med 73(06), 599–602, 2007.
57. N.Li, J.-H.Liu, J.Zhang, and B.-Y.Yu: Comparative evaluation of cytotoxicity and antioxidative activity of 20 flavonoids. J Agr Food Chem 56(10), 3876–3883, 2008.
58. W.Bhouri, I.Bouhlel, J.Boubaker, S.Kilani, K.Ghedira, et al.: Induction of apoptosis in human lymphoblastoid cells by kaempferol 3-O-beta-isorhamninoside and rhamnocitrin 3-O-beta-isorhamninoside from Rhamnus alaternus L. (Rhamnaceae). Cell Prolif 44(3), 283–290, 2011.
59. Y.J.Jang, J.Kim, J.Shim, J.Kim, S.Byun, et al.: Kaempferol attenuates 4-hydroxynonenal-induced apoptosis in PC12 cells by directly inhibiting NADPH oxidase. J Pharmacol Exp Ther 337(3), 747–754, 2011.
60. J.M.Kim, E.K.Lee, D.H.Kim, B.P.Yu, and H.Y.Chung: Kaempferol modulates pro-inflammatory NF-κB activation by suppressing advanced glycation endproducts-induced NADPH oxidase. Age 32(2), 197–208, 2010.
61. M.J.Park, E.K.Lee, H.-S.Heo, M.-S.Kim, B.Sung, et al.: The anti-inflammatory effect of kaempferol in aged kidney tissues: the involvement of nuclear factor-κ B via nuclear factor-inducing kinase/I κ B kinase and mitogen-activated protein kinase pathways. J Med Food 12(2), 351–358, 2009.
62. D.A.Acker, K.Kramer, J.A.Grimbergen, D.J.Berg, W.J.Vijgh, et al.: Monohydroxyethylrutoside as protector against chronic doxorubicin‐induced cardiotoxicity. British J Pharmacol 115(7), 1260–1264, 1995.
63. F.A.van Acker, S.A.van Acker, K.Kramer, G.R.Haenen, A.Bast, et al.: 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res 6(4), 1337–1341, 2000.
64. A.M.Bruynzeel, P.P.Mul, J.Berkhof, A.Bast, H.W.Niessen, et al.: The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Cancer Chemoth Pharm 58(5), 699–702, 2006.
65. A.M.Bruynzeel, S.Vormer-Bonne, A.Bast, H.W.Niessen, and W.J.van der Vijgh: Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice. Cancer Chemoth Pharm 60(4), 509–514, 2007.
66. M.A.El Hassan, H.Verheul, A.Jorna, C.Schalkwijk, J.Van Bezu, et al.: The new cardioprotector monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro. British J Cancer 89(2), 357–362, 2003.
67. A.M.Bruynzeel, M.A.El Hassan, C.Schalkwijk, J.Berkhof, A.Bast, et al.: Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. Br J Cancer 96(6), 937–943, 2007.
68. S.A.van Acker, E.Boven, K.Kuiper, D.J.van den Berg, J.A.Grimbergen, et al.: Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res 3(10), 1747–1754, 1997.
69. A.M.Willems, A.M.Bruynzeel, M.A.Kedde, C.J.Van Groeningen, A.Bast, et al.: A phase I study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemother Pharmacol 57(5), 678–684, 2006.
70. A.M.Bruynzeel, H.W.Niessen, J.G.Bronzwaer, J.J.van der Hoeven, J.Berkhof, et al.: The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. Br J Cancer 97(8), 1084–1089, 2007.
71. S.H.More, S.B.Sathe, A.A.Sonawane, A.P.Jadhav, and V.J.Kadam: Estimation of naringin and hesperidin from citrus fruits by HPTLC. Am J Pharm Res 3(8), 6175–6183, 2013.
72. E.Middleton Jr and C.Kandaswami: Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol 43(6), 1167–1179, 1992.
73. Y.-C.Kao, C.Zhou, M.Sherman, C.A.Laughton, and S.Chen: Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect 106(2), 85, 1998.
74. N.Guthrie and K.Carroll: Inhibition of mammary cancer by citrus flavonoids. In: Flavonoids in the Living System, Manthey J and Buslig B (eds.). New York: Springer, 1998, pp. 227–236.
75. S.-M.Jeon, Y.B.Park, and M.-S.Choi: Antihypercholesterolemic property of naringin alters plasma and tissue lipids, cholesterol-regulating enzymes, fecal sterol and tissue morphology in rabbits. Clin Nutr 23(5), 1025–1034, 2004.
76. G.C.Jagetia and T.K.Reddy: Alleviation of iron induced oxidative stress by the grape fruit flavanone naringin in vitro. Chem Biol Interact 190(2), 121–128, 2011.
77. H.M.Arafa, M.F.Abd-Ellah, and H.F.Hafez: Abatement by naringenin of doxorubicin-induced cardiac toxicity in rats. J Egypt Natl Canc Inst 17, 291–300, 2005.
78. G.C.Jagetia and T.K.Reddy: The grape fruit flavonone naringin protects mice against doxorubicin-induced cardiotoxicity. J Mol Biochem 3(1), 34–49, 2014.
79. S.S.Shiromwar and V.R.Chidrawar: Combined effects of p-coumaric acid and naringenin against doxorubicin-induced cardiotoxicity in rats. Pharmacognosy Res 3(3), 214, 2011.
80. X.Han, D.Ren, P.Fan, T.Shen, and H.Lou: Protective effects of naringenin-7-O-glucoside on doxorubicin-induced apoptosis in H9C2 cells. Eur J Pharma 581(1), 47–53, 2008.
81. X.Han, J.Pan, D.Ren, Y.Cheng, P.Fan, et al.: Naringenin-7-O-glucoside protects against doxorubicin-induced toxicity in H9c2 cardiomyocytes by induction of endogenous antioxidant enzymes. Food Chem Toxicol 46(9), 3140–3146, 2008.
82. C.Cavin, M.Marin-Kuan, S.Langouët, C.Bezençon, G.Guignard, et al.: Induction of Nrf2-mediated cellular defenses and alteration of phase I activities as mechanisms of chemoprotective effects of coffee in the liver. Food Chem Toxicol 46(4), 1239–1248, 2008.
83. S.Manandhar, J.-M.Cho, J.Kim, T.W.Kensler, and M.-K.Kwak: Induction of Nrf2-regulated genes by 3 H-1, 2-dithiole-3-thione through the ERK signaling pathway in murine keratinocytes. Eur J Pharmacol 577(1), 17–27, 2007.
84. S.B.Cullinan, D.Zhang, M.Hannink, E.Arvisais, R.J.Kaufman, et al.: Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23(20), 7198–7209, 2003.
85. P.H.Sugden and A.Clerk: Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myocytes. Antioxid Redox Signal 8(11–12), 2111–2124, 2006.
86. V.M.R.Papasani, B.Hanumantharayappa, and A.Annapurna: Cardioprotective effect of naringin against doxorubicin induced cardiomyopathy in rats. Indo Am J Pharma Res 4(5), 2593–2598, 2014.
87. C.-C.Chuang, K.Martinez, G.Xie, A.Kennedy, A.Bumrungpert, et al.: Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-α–mediated inflammation and insulin resistance in primary human adipocytes. Am J Clin Nutr 92(6), 1511–1521, 2010.
88. J.-Y.Chen, R.-Y.Hu, and H.-C.Chou: Quercetin-induced cardioprotection against doxorubicin cytotoxicity. J Biomed Sci 20(1), 95, 2013.
89. A.S.Nazmi, S.J.Ahmad, K.K.Pillai, M.Akhtar, A.Ahmad, et al.: Protective effects of Bombyx mori, quercetin and benazepril against doxorubicin induced cardiotoxicity and nephrotoxicity. J Saudi Chem Soc 2013.
90. A.I.Matouk, A.Taye, G.H.Heeba, and M.A.El-Moselhy: Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. Environ Toxicol Pharmacol 36(2), 443–450, 2013.
91. I.H.Ismail, C.Andrin, D.McDonald, and M.J.Hendzel: BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol 191(1), 45–60, 2010.
92. W.Chatoo, M.Abdouh, J.David, M.-P.Champagne, J.Ferreira, et al.: The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. J Neurosci 29(2), 529–542, 2009.
93. Q.Dong, L.Chen, Q.Lu, S.Sharma, L.Li, et al.: Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi‐1 expression. Br J Pharmacol 171(19):4440–4454, 2014.
94. T.X.Pei, C.Q.Xu, B.Li, Z.R.Zhang, X.X.Gao, et al.: Protective effect of quercetin against adriamycin-induced cardiotoxicity and its mechanism in mice. Yao Xue Xue Bao 42(10), 1029–1033, 2007.
95. M.Atanassova and V.Bagdassarian: Rutin content in plant products. J Univers Chem Technol Metallurgy 44(2), 201–203, 2009.
96. C.K.Hui, Z.A.Mahdy, N.A.M.M.Nordin, A.Ugusman and Z.Zakaria: Flavonoids of Piper sarmentosum and its cytoprotective effects against oxidative stress. Experiment Clin Sci Inter 11,705–714, 2012.
97. A.Ugusman, Z.Zakaria, K.H.Chua, N.A.Megat Mohd Nordin, and Z.Abdullah Mahdy: Role of rutin on nitric oxide synthesis in human umbilical vein endothelial cells. Sci World J, ID 169370, 2014.
98. P.Ashokkumar and G.Sudhandiran: Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother 62(9), 590–597, 2008.
99. Y.Nishitani, K.Yamamoto, M.Yoshida, T.Azuma, K.Kanazawa, et al.: Intestinal anti‐inflammatory activity of luteolin: role of the aglycone in NF‐κB inactivation in macrophages co‐cultured with intestinal epithelial cells. Biofactors 39(5), 522–533, 2013.
100. T.Xu, D.Li, and D.Jiang: Targeting cell signaling and apoptotic pathways by luteolin: cardioprotective role in rat cardiomyocytes following ischemia/reperfusion. Nutrients 4(12), 2008–2019, 2012.
101. J.Y.Salib, H.N.Michael, and E.F.Eskande: Anti-diabetic properties of flavonoid compounds isolated from Hyphaene thebaica epicarp on alloxan induced diabetic rats. Pharmacognosy Res 5(1), 22, 2013.
102. P.Ashokkumar and G.Sudhandiran: Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/β-catenin pathway. Invest New Drugs 29(2), 273–284, 2011.
103. Y.Sadzuka, T.Sugiyama, K.Shimoi, N.Kinae, and S.Hirota: Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol Lett 92(1), 1–7, 1997.
104. S.-Q.Wang, X.-Z.Han, X.Li, D.-M.Ren, X.-N.Wang, et al.: Flavonoids from Dracocephalum tanguticum and their cardioprotective effects against doxorubicin-induced toxicity in H9c2 cells. Bioorg Med Chem Lett 20(22), 6411–6415, 2010.
105. C.Manach, G.Williamson, C.Morand, A.Scalbert, and C.Rémésy: Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81(1), 230S–242S, 2005.
106. W.Mullen, C.A.Edwards, and A.Crozier: Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl-and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br J Nutr 96(01), 107–116, 2006.
107. H.Rupasinghe, C.M.Ronalds, B.Rathgeber, and R.A.Robinson: Absorption and tissue distribution of dietary quercetin and quercetin glycosides of apple skin in broiler chickens. J Sci Food Agric 90(7), 1172–1178, 2010.
108. S.H.Thilakarathna, H.Rupasinghe, and P.W.Needs: Apple peel bioactive rich extracts effectively inhibit in vitro human LDL cholesterol oxidation. Food Chem 138(1), 463–470, 2013.
109. Y.Panahi, M.S.Hosseini, N.Khalili, E.Naimi, M.Majeed, et al.: Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin Nutr 34(6) 1101–1108, 2015.
110. Y.Panahi, N.Khalili, M.S.Hosseini, M.Abbasinazari, and A.Sahebkar: Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 22(5), 851–857, 2014.
111. A.Sahebkar: Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 11(2), 123, 2014.
112. A.Sahebkar: Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res: PTR 28(5), 633–642, 2014.
113. A.Sahebkar, A.Mohammadi, A.Atabati, S.Rahiman, S.Tavallaie, et al.: Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res: PTR 27(12), 1883–1888, 2013.
114. A.Sahebkar: Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39(2), 197–208, 2013.
115. A.Mohammadi, A.Sahebkar, M.Iranshahi, M.Amini, R.Khojasteh, et al.: Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res: PTR 27(3), 374–379, 2013.
116. A.Sahebkar, G.T.Chew and G.F.Watts: Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 56(47–66), 2014.
117. N.Venkatesan: Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124(3), 425–427, 1998.
118. A.V.Swamy, S.Gulliaya, A.Thippeswamy, B.C.Koti, and D.V.Manjula: Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol 44(1), 73–77, 2012.
119. S.Imbaby, M.Ewais, S.Essawy, and N.Farag: Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats. Hum Exp Toxicol 33(8), 800–813, 2014.
120. L.Hosseinzadeh, J.Behravan, F.Mosaffa, G.Bahrami, A.Bahrami, et al.: Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem Toxicol 49(5), 1102–1109, 2011.
121. L.Hosseinzadeh, J.Behravan, F.Mosaffa, G.Bahrami, A.Bahrami, et al.: Effect of curcumin on doxorubicin-induced cytotoxicity in H9c2 cardiomyoblast cells. Iranian J Basic Med Sci 14, 161, 2011.
122. N.Ribeiro, F.Thuaud, C.Nebigil, and L.Désaubry: Recent advances in the biology and chemistry of the flavaglines. Bioorg Med Chem 20(6), 1857–1864, 2012.
123. N.Ribeiro, F.Thuaud, Y.Bernard, C.Gaiddon, T.Cresteil, et al.: Flavaglines as potent anticancer and cytoprotective agents. J Med Chem 55(22), 10064–10073, 2012.
124. Y.Bernard, N.Ribeiro, F.Thuaud, G.Türkeri, R.Dirr, et al.: Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27. PLoS ONE 6(10), 2011.
125. K.Flora, M.Hahn, H.Rosen, and K.Benner: Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93(2), 139–143, 1998.
126. K.Wellington and B.Jarvis: Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15(7), 465–489, 2001.
127. N.Dixit, S.Baboota, K.Kohli, S.Ahmad, and J.Ali: Silymarin: a review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol 39(4), 172–179, 2007.
128. P.JPsotová, C.ŠChlopčíková, F.Grambal, V.Šimánek, and J.Ulrichová: Influence of silymarin and its flavonolignans on doxorubicin‐iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res 16(S1), 63–67, 2002.
129. P.S.Makena, S.C.Pierce, K.T.Chung, and S.E.Sinclair: Comparative mutagenic effects of structurally similar flavonoids quercetin and taxifolin on tester strains Salmonella typhimurium TA102 and Escherichia coli WP‐2 uvrA. Environ Mol Mutagen 50(6), 451–459, 2009.
130. Š.Chlopčíková, J.Psotová, P.Miketová, and V.Šimánek: Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res 18(2), 107–110, 2004.
131. N.A.El-Shitany, S.El-Haggar, and K.El-desoky: Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol 46(7), 2422–2428, 2008.
132. A.Rašković, N.Stilinović, J.Kolarović, V.Vasović, S.Vukmirović, et al.: The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules 16(10), 8601–8613, 2011.
133. A.A.Fouad and M.T.Yacoubi: Mechanisms underlying the protective effect of eugenol in rats with acute doxorubicin cardiotoxicity. Arch Pharm Res 34(5), 821–828, 2011.
134. E.Fadillioglu, E.Oztas, H.Erdogan, M.Yagmurca, S.Sogut, et al.: Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol 24(1), 47–52, 2004.
135. D.S.Kim, E.R.Woo, S.W.Chae, K.C.Ha, G.H.Lee, et al.: Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-κB activation. Life Sci 80(4), 314–323, 2007.
136. A.Russo, R.Longo, and A.Vanella: Antioxidant activity of propolis: role of caffeic acid phenethyl ester and galangin. Fitoterapia 73, S21–S29, 2002.
137. X.-L.Wang, X.Wang, L.-L.Xiong, Z.YcZhu, H.-L.Chen, J.-X.Chen, et al.: Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. J Cardiovasc Pharmacol 62, 512–523, 2013.
138. S.Granados-Principal, J.L.Quiles, C.L.Ramirez-Tortosa, P.Sanchez-Rovira, and M.C.Ramirez-Tortosa: Hydroxytyrosol: from laboratory investigations to future clinical trials. Nutr Rev 68(4), 191–206, 2010.
139. S.Granados-Principal, N.El-Azem, R.Pamplona, C.Ramirez-Tortosa, M.Pulido-Moran, et al.: Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer. Biochem Pharmacol 90(1), 25–33, 2014.
140. I.Andreadou, F.Sigala, E.K.Iliodromitis, M.Papaefthimiou, C.Sigalas, et al.: Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol 42(3), 549–558, 2007.
141. I.Andreadou, M.Papaefthimiou, A.Zira, M.Constantinou, F.Sigala, et al.: Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. NMR Biomed 22(6), 585–592, 2009.
142. M.Kim and R.Tian: Targeting AMPK for cardiac protection: opportunities and challenges. J Mol Cell Cardiol 51(4), 548–553, 2011.
143. J.A.Menendez, J.Joven, G.Aragones, E.Barrajon-Catalan, R.Beltran-Debon, et al.: Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle 12(4), 555–578, 2013.
144. I.Andreadou, E.Mikros, K.Ioannidis, F.Sigala, K.Naka, et al.: Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. J Mol Cell Cardiol 69, 4–16, 2014.
145. R.Pangeni, J.K.Sahni, J.Ali, S.Sharma, and S.Baboota: Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Del 11(8), 1285–1298, 2014.
146. E.D.Brookins Danz, J.Skramsted, N.Henry, J.A.Bennett, and R.S.Keller: Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 46(12), 1589–1597, 2009.
147. E.Tatlidede, Ş.ÖŞehirli, V.-Ö.AVelioglu-Ögüç, S.Çetinel, B.Ç.Yegen, et al.: Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 43(3), 195–205, 2009.
148. C.Zhang, Y.Feng, S.Qu, X.Wei, H.Zhu, et al.: Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 90(3), 538–545, 2011.
149. F.A.Pinarli, N.N.Turan, F.G.Pinarli, A.Okur, D.Sönmez, et al.: Resveratrol and adipose-derived mesenchymal stem cells are effective in the prevention and treatment of doxorubicin cardiotoxicity in rats. Pediatr Hematol Oncol 30(3), 226–238, 2013.
150. Z.Cao and Y.Li: Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 489(1–2), 39–48, 2004.
151. D.Beher, J.Wu, S.Cumine, K.W.Kim, S.-C.Lu, et al.: Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74(6), 619–624, 2009.
152. A.J.Dirks-Naylor: The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci 93(24), 913–916, 2013.
153. X.Xu, K.Chen, S.Kobayashi, D.Timm, and Q.Liang: Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther 341(1), 183–195, 2012.
154. E.Wenzel and V.Somoza: Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49(5), 472–481, 2005.
155. J.Gu, Z.P.Song, D.M.Gui, W.Hu, Y.G.Chen, et al.: Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc Toxicol 12(4), 341–349, 2012.
156. M.H.Arafa, N.S.Mohammad, H.H.Atteia, and H.R.Abd-Elaziz: Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem 70(3), 701–711, 2014.
157. F.Bernuzzi, S.Recalcati, A.Alberghini, and G.Cairo: Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation. Chem Biol Interact 177(1), 12–20, 2009.
158. J.Díaz-Chávez, M.A.Fonseca-Sánchez, E.Arechaga-Ocampo, A.Flores-Pérez, Y.Palacios-Rodríguez, et al.: Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy. PLoS ONE 8(5), e64378, 2013.
159. T.H.Kim, Y.J.Shin, A.J.Won, B.M.Lee, W.S.Choi, et al.: Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 1840(1), 615–625, 2014.
160. A.M.Osman, S.E.Al-Harthi, O.M.AlArabi, M.F.Elshal, W.S.Ramadan, et al.: Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals. Cancer Cell Int 13(52), 2013.
161. L.J.Carlson, B.Cote, A.W.Alani, and D.A.Rao: Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci 103(8):2315–2322, 2014.
162. S.H.Zhang, W.Q.Wang, and J.L.Wang: Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo. Acta Pharmacol Sin 30(11), 1479–1487, 2009.
163. P.G.Nayak, P.Paul, P.Bansal, N.G.Kutty, and K.S.Pai: Sesamol prevents doxorubicin-induced oxidative damage and toxicity on H9c2 cardiomyoblasts. J Pharm Pharmacol 65(7), 1083–1093, 2013.
164. A.Chennuru and M.T.Saleem: Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. Biomed Res Int 2013, 934239, 2013.
165. Y.Liang: Clinical study on “sini” decoction on treating stenocardia for coronary heart disease. Zhong Yao Cai 28(8), 737–739, 2005.
166. Y.L.Chen, X.D.Zhuang, Z.W.Xu, L.H.Lu, H.L.Guo, et al.: Higenamine combined with [6]-gingerol suppresses doxorubicin-triggered oxidative stress and apoptosis in cardiomyocytes via upregulation of PI3K/Akt pathway. Evid Based Complement Alternat Med 2013, 970490, 2013.
167. W.M.El-Bakly, M.L.Louka, A.M.El-Halawany, and M.F.Schaalan: 6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation. Cancer Chemother Pharmacol 70(6), 833–841, 2012.
168. N.Balasundram, K.Sundram, and S.Samman: Phenolic compounds in plants and agri-industrial by-products: antioxidant activity, occurrence, and potential uses. Food Chem 99(1), 191–203, 2006.
169. A.Michalak: Phenolic compounds and their antioxidant activity in plants growing under heavy metal stress. Pol J Environl Stud 15(4), 523, 2006.
170. B.L.Milić, S.M.Djilas, and J.M.Čanadanović-Brunet: Antioxidative activity of phenolic compounds on the metal-ion breakdown of lipid peroxidation system. Food Chem 61(4), 443–447, 1998.
171. C.Camello-Almaraz, P.J.Gomez-Pinilla, M.J.Pozo, and P.J.Camello: Mitochondrial reactive oxygen species and Ca2+ signaling. Am J Physiol-Cell Physiol 291(5), C1082–C1088, 2006.
172. W.Gen, M.Tani, J.Takeshita, Y.Ebihara, and K.Tamaki: Mechanisms of Ca2+ overload induced by extracellular H2O2 in quiescent isolated rat cardiomyocytes. Basic Res Cardiol 96(6), 623–629, 2001.
173. Q.Zeng, Q.Zhou, F.Yao, S.T.O'Rourke, and C.Sun: Endothelin-1 regulates cardiac L-type calcium channels via NAD (P) H oxidase-derived superoxide. J Pharmacol Exp Ther 326(3), 732–738, 2008.
174. Y.-W.Zhang, J.Shi, Y.-J.Li, and L.Wei: Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp 57(6), 435–445, 2009.
175. D.-S.Kim, E.-R.Woo, S.-W.Chae, K.-C.Ha, G.-H.Lee, et al.: Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-κB activation. Life Sci 80(4), 314–323, 2007.
176. H.Li, H.Gu, and B.Sun: Protective effects of pyrrolidine dithiocarbamate on myocardium apoptosis induced by adriamycin in rats. Int J Cardiol 114(2), 159–165, 2007.
177. G.Velderrain-Rodríguez, H.Palafox-Carlos, A.Wall-Medrano, J.Ayala-Zavala, C.O.Chen, et al.: Phenolic compounds: their journey after intake. Food Funct 5(2), 189–197, 2014.
178. L.Rubio, A.Macia, and M.-J.Motilva: Impact of various factors on pharmacokinetics of bioactive polyphenols: an overview. Curr Drug Metab 15(1), 62–76, 2014.
179. Z.Li, H.Jiang, C.Xu and L.Gu: A review: using nanoparticles to enhance absorption and bioavailability of phenolic phytochemicals. Food Hydrocoll 43, 153–164, 2015.